The SPN-830 Apomorphine Infusion Device NDA that Supurnus resubmitted has been accepted by the FDA.

Published Date: 05 Nov 2023

SPN-830 treatment caused patients with Parkinson's disease to have much longer OFF times than placebo in the phase 3 TOLEDO trial.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Relationship-building key to addressing oncologist shortages in rural care

2.

New protein target discovered for childhood medulloblastomas

3.

Acalabrutinib + Venetoclax Combo Earns FDA Nod for CLL

4.

Papillary thyroid cancer: New markers offer hope for tailored treatment

5.

Jazz Seeks Second-Line Lurbinectedin SCLC Withdrawal


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot